FORT LAUDERDALE, Fla., June 1, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals, Inc. (Pink Sheets: NOUV) is pleased to announce that the Company has named Melissa Walker as its new CEO and President.
Ms. Walker is a seasoned business strategist and communications professional. As an independent strategic marketing consultant for over 10 years, Ms. Walker has successfully managed short- and long-term projects that directly impacted profitability and growth for her clients, most of which were Fortune 100 companies. During her career she has worked across diverse industries, including consumer products, energy, healthcare, manufacturing, food and beverage, insurance, financial, chemical, and technology. Her expertise in all things marketing has led to her clients’ success in the areas of brand awareness, new product development, go-to-market strategies, investor awareness, and public relations campaigns. Ms. Walker assumed her new position on May 9.
“I’m honored to be a part of Nouveau Life and energized by the potential the Company has. In my short time here, we’ve already made some exciting moves with the formal name change, the release of our first product, and adding online sales capabilities. I plan to leverage that momentum to keep Nouveau Life moving forward,” stated Ms. Walker. “Starting a company is never easy. I appreciate the patience consumers and investors have afforded Nouveau Life up to this point. I hope they are as excited as I am about the Company’s new direction and recent progress. Remember, objects in motion tend to stay in motion, and Nouveau Life is certainly moving.”
About Nouveau Life Pharmaceuticals
The Company, formerly known as Hybrid Fuels, Inc., was incorporated in the state of Nevada in 1998 as Polo Equities. It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies.
Forward-Looking Statements - This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Nouveau Life Pharmaceuticals, Inc. undertakes no obligation to update such statements.
SOURCE Nouveau Life Pharmaceuticals, Inc.
